http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018208107-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_02ac9bd35856d8efcae5699b55f9a19c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-047 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-047 |
| filingDate | 2018-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfe2156b3f00fa2c5f9ea9d4c4aca75e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e521e512a3d5314c0bd59dd308fc2034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2667c85b3bcbf97fee63ec9eedcd7c7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2d585010647bdab62e4fd54ece15032 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_637f2e1147f793f83f0e51810e9f3dd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e64e23a157369457a7e062def413d32 |
| publicationDate | 2018-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2018208107-A1 |
| titleOfInvention | Composition for alleviating, preventing, or treating somnipathy or composition for suppressing resistance to benzodiazepine binding site agonist of gaba-a receptor or for alleviating side-effect of benzodiazepine binding site agonist of gaba-a receptor, each composition comprising phloroglucinol as effective ingredient |
| abstract | A pharmaceutical composition for preventing or treating somnipathy or a health function food composition for alleviating somnipathy, each composition comprising phloroglucinol as an effective ingredient, according to the present invention can quickly and reliably induce or maintain sleep. Meanwhile, the composition can prevent a repeated awakening phenomenon without changing a physiological sleep architecture, has no residual sedation, which may particularly give rise to incomplete daytime activities or recognition ability, does not induce resistance after long-term administration, and does not generate a side-effect of conventional benzodiazepine binding side agonist of the GABA-A receptor. In addition, a pharmaceutical composition or a health functional food composition comprising phloroglucinol as an effective ingredient for suppressing resistance to a benzodiazepine binding site agonist of the GABA-A receptor or alleviating a side effect of a benzodiazepine binding site agonist of the GABA-A receptor, according to the present invention can alleviate a side effect of a benzodiazepine binding side agonist of the GABA-A receptor or suppress resistance that occurs with the long-term administration of a benzodiazepine binding site agonist of the GABA-A receptor. Further, a pharmaceutical composition comprising phloroglucinol and a benzodiazepine binding site agonist of the GABA-A receptor as effective ingredients for preventing or treating somnipathy according to the present invention has a reduced content of the benzodiazepine binding site agonist of the GABA-A receptor, which may increase the quantity of sleep, but degrade the quality of sleep, acting as a cause of various side effects, whereby the side effects of the benzodiazepine binding site agonist of the GABA-A receptor can be reduced or the resistance occurring with the long-term administration of the benzodiazepine binding site agonist of the GABA-A receptor can be suppressed. |
| priorityDate | 2017-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 82.